Cardiac Surgery
Cardiac surgery at Baylor Scott & White The Heart Hospital stands as a beacon of excellence in the field of cardiovascular medicine.
Where vision meets precision
2025 Outcomes
Renowned for our innovative techniques, leading-edge technology and patient-centered care, we have consistently achieved remarkable outcomes that set the national benchmark for quality and success. Backed by a team of highly skilled surgeons, medical expertise and a commitment to continuous improvement, cardiac surgery has earned its reputation as a leader in cardiac medicine. With numerous accomplishments underscoring its dedication, we continue to advance cardiovascular surgery for patients both locally and globally.
Accomplishments
- Our robotics program expanded this year with the initiation of our aortic valve replacement (AVR) program, and we completed the first robotic triple valve. Our mortality rate for robotic AVR is 0%.
- We are the second-leading enrolling facility for the IMPACT trial, which demonstrates the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients.
- We are spearheading the North American Ross Consortium (NARC) with three other programs to help standardize surgical techniques to improve long-term success
VOLUMES/QUALITY
PLANO & DENTON
120
MVRR + CABG
248
AVR + CABG
347
AVR
778
MVRR
2,780
ISO CABG
4,492
MULTIPROCEDURAL
Plano recently earned 3-star ratings in all six Society of Thoracic Surgeons (STS) cardiac surgery categories. These results place Plano in the top 1% of programs in the country. Denton earned 3-star STS ratings in the CABG and Multiprocedural categories.
PLANO 3-STAR IN ALL STS CATEGORIES
Isolated CABG | Isolated AVR | AVR + CABG
Isolated MVRR | MVRR + CABG | Multi-Procedural
239 Cardiac robotic
procedures performed
(MARCH 2024 - FEB. 2025)
Ross procedure volumes
58% growth between FY 2023 and FY 2024
0% mortality, renal failure and
stroke in the last three years
ROSS PROCEDURE VOLUME
30
20
10
0
FY22
FY23
FY24
2024 predicted and observed risk-adjusted mortality (as compared to STS predicted mortality)
| PLANO | DENTON | STS | |||
|---|---|---|---|---|---|
| Predicted | Observed | Predicted | Observed | Predicted | |
| ISO CABG | 1.50% | 0.66% | 1.40% | 2.09% | 2.05% |
| ISO AVR | 1.76% | 0.00% | 1.03% | 0.00% | 1.76% |
| AVR + CABG | 2.61% | 0.00% | 2.50% | 0.00% | 3.60% |
| MV REPAIR | 0.69% | 0.00% | — | — | 0.93% |
| MV REPLACE | 5.34% | 1.75% | — | — | 4.87% |
We recently launched the Heart Surgery Care Companion digital app, which is designed to support our cardiovascular patient population both before surgery and for 30 days post-discharge. Over a six-month period, the program delivered significant outcomes, including a 24% reduction in 30-day readmissions, with 91% of users reporting high satisfaction leading to a decreased need for patients to contact their surgeons.
Innovations
- We are proud to be part of the Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) trial, an international, multicenter cardiac surgery trial aimed at improving stroke prevention for cardiac surgery patients, focusing on the effectiveness of left atrial appendage exclusion in preventing ischemic stroke of systemic embolism in patients with risk factors for AFib or ischemic stroke.
- We were a key enroller in the Cardioband FIT clinical trial, an early feasibility study that evaluated the treatment of functional tricuspid regurgitation via annular reduction with the Cardioband Tricuspid Valve Reconstruction System.
Among cardiac surgery’s elite nationally
Achieving the highest three-star rating in all six categories from STS
3 Stars
3 Stars
3 Stars
3 Stars
3 Stars
3 Stars
Previous
Next